(RTTNews) – Charles River Laboratories International, Inc. (CRL) announced Monday that it has signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions.
{iframe}https://www.nasdaq.com/articles/charles-river-to-acquire-vigene-biosciences-for-%24292.5-mln-in-cash-quick-facts-2021-05-17?amp{/iframe}